Konstantinos Xynos - Apr 1, 2023 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role
Chief Medical Officer
Signature
/s/ Jean Franchi, attorney-in-fact
Stock symbol
REPL
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/4/2023, 08:02 PM
Previous filing
Dec 5, 2022
Next filing
May 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Award $0 +50K +70.62% $0.00 121K Apr 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REPL Employee Stock Option (right to buy) Award $0 +75K $0.00 75K Apr 1, 2023 Common Stock 75K $17.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer.
F2 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.